Pharmaron Beijing Adjusts Valuation Metrics Amidst Financial Performance Shifts

Pharmaron Beijing Co., Ltd., a midcap player in the miscellaneous industry, has recently undergone an adjustment in evaluation that reflects shifts in its financial metrics. The company currently presents a P/E ratio of 22, indicating its valuation relative to earnings. Additionally, the Price to Book Value stands at 2.86, suggesting a premium over its book value.
The stock's EV to EBIT is recorded at 23.11, while the EV to EBITDA is at 17.50, providing insights into its operational efficiency. The EV to Sales ratio is noted at 3.37, which can be indicative of how the market values its sales relative to enterprise value. The PEG ratio, a measure of growth relative to valuation, is at 0.86, reflecting the company's growth prospects in relation to its current price.

Pharmaron's return on capital employed (ROCE) is reported at 10.99%, and its return on equity (ROE) is at 13.15%. These metrics contribute to the overall assessment of the company's financial health and market positioning.

For more insights on Pharmaron Beijing Co., Ltd. and its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.